Get the Stockscreener App
4.82
7.11%
0.32
Monte Rosa Therapeutics Inc stock is traded at $4.82, with a volume of 421.06K.
It is up +7.11% in the last 24 hours and down -14.84% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$4.50
Open:
$4.52
24h Volume:
421.06K
Relative Volume:
0.96
Market Cap:
$297.68M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-2.1518
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
+5.24%
1M Performance:
-14.84%
6M Performance:
-22.51%
1Y Performance:
-14.39%
1-Day Range:
$4.515
$4.915
1-Week Range:
$4.30
$4.915
52-Week Range:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.82 | 281.62M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
What’s the recovery path for long term holders of Monte Rosa Therapeutics Inc.2025 Winners & Losers & Technical Entry and Exit Tips - Newser
How hedge fund analytics apply to Monte Rosa Therapeutics Inc. stockProduct Launch & High Return Trade Opportunity Guides - Newser
What Fibonacci levels say about Monte Rosa Therapeutics Inc. reboundDay Trade & Expert Approved Trade Ideas - Newser
Tick level data insight on Monte Rosa Therapeutics Inc. volatilityWeekly Profit Recap & Smart Allocation Stock Tips - Newser
Will Monte Rosa Therapeutics Inc. rebound enough to break even2025 Retail Activity & Long-Term Growth Stock Strategies - Newser
Statistical indicators supporting Monte Rosa Therapeutics Inc.’s strength2025 Market Trends & AI Forecasted Entry and Exit Points - Newser
What momentum shifts mean for Monte Rosa Therapeutics Inc.Quarterly Market Summary & Weekly Chart Analysis and Guides - Newser
Can you recover from losses in Monte Rosa Therapeutics Inc.Weekly Trade Review & Daily Oversold Stock Bounce Ideas - Newser
Analyzing recovery setups for Monte Rosa Therapeutics Inc. investors2025 Retail Activity & Weekly High Momentum Picks - Newser
Risk vs reward if holding onto Monte Rosa Therapeutics Inc.Dollar Strength & AI Enhanced Execution Alerts - Newser
Should you wait for a breakout in Monte Rosa Therapeutics Inc.July 2025 Opening Moves & Stock Market Timing Techniques - Newser
Is Monte Rosa Therapeutics Inc. stock ready for a breakout2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser
Leading vs lagging indicators on Monte Rosa Therapeutics Inc. performancePortfolio Update Summary & AI Driven Stock Price Forecasts - Newser
Relative strength of Monte Rosa Therapeutics Inc. in sector analysisJuly 2025 Selloffs & Risk Managed Investment Signals - Newser
Can Monte Rosa Therapeutics Inc. withstand a market correctionWeekly Trade Review & Real-Time Volume Analysis Alerts - 선데이타임즈
What is the dividend yield of Monte Rosa Therapeutics Inc.Quarterly Trade Summary & Precise Buy Zone Tips - thegnnews.com
Applying big data sentiment scoring on Monte Rosa Therapeutics Inc.Weekly Risk Summary & Reliable Intraday Trade Alerts - Newser
How to integrate Monte Rosa Therapeutics Inc. into portfolio analysis tools - Newser
How institutional ownership impacts Monte Rosa Therapeutics Inc. stockJuly 2025 PostEarnings & Community Consensus Trade Alerts - Newser
Will Monte Rosa Therapeutics Inc. bounce back from current supportPortfolio Profit Report & Expert Verified Movement Alerts - Newser
How Monte Rosa Therapeutics Inc. stock performs during market volatilityJuly 2025 Price Swings & Verified Stock Trade Ideas - Newser
Using data tools to time your Monte Rosa Therapeutics Inc. exitQuarterly Earnings Summary & Reliable Intraday Trade Alerts - Newser
Can machine learning forecast Monte Rosa Therapeutics Inc. recoveryMarket Activity Recap & Technical Analysis for Trade Confirmation - Newser
Should you hold or exit Monte Rosa Therapeutics Inc. now2025 Bull vs Bear & Smart Money Movement Alerts - Newser
Will earnings trigger a reversal in Monte Rosa Therapeutics Inc.Trade Risk Report & Long-Term Safe Investment Plans - Newser
Relief Rally in Monte Rosa Therapeutics Inc. Stock — Can It HoldJuly 2025 Opening Moves & Real-Time Stock Price Movement Reports - 선데이타임즈
Monte Rosa Therapeutics Inc. Reaches Critical Trendline SupportAnalyst Upgrade & AI Driven Price Forecasts - sundaytimes.kr
Real time scanner hits for Monte Rosa Therapeutics Inc. explainedCEO Change & Entry Point Confirmation Signals - Newser
Published on: 2025-08-14 07:05:55 - Newser
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attentionWeekly Portfolio Update with ROI Focus - Newser
How to recover losses in Monte Rosa Therapeutics Inc. stockAI Generated Momentum Stock Forecast Guide - Newser
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Monte Rosa Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Monte Rosa Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Monte Rosa Therapeutics Reports Q2 2025 Earnings - TipRanks
Monte Rosa Therapeutics Q2 2025 Earnings: Collaboration Revenue Surges, Net Loss Widened - AInvest
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monte Rosa Therapeutics Inc Stock (GLUE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leo Chandra P. | Director |
Mar 24 '25 |
Buy |
5.84 |
10,000 |
58,383 |
10,000 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 28 '24 |
Sale |
9.66 |
89,990 |
869,240 |
2,007,948 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 29 '24 |
Sale |
9.16 |
67,905 |
621,801 |
1,573,453 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):